Federal contract award
75F40120C00200
BAA SETTING PATIENT-CENTRIC QUALITY STANDARDS (PCQS) FOR MODIFIED RELEASE (MR) ORAL DRUG PRODUCTS WITH BIOPREDICTIVE IN VITRO DISSOLUTION-MODELS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AZ11 — OTHER RESEARCH AND DEVELOPMENT - BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $2.2M |
| Current contract value | $2.2M |
| Potential contract value / ceiling | $2.2M |
| Start date | Sep 22, 2020 |
| Current end date | Mar 29, 2026 |
| Potential end date | Mar 29, 2026 |
| Latest award activity | Aug 15, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 15, 2025 | P00004 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO MARCH 29, 2026. |
| May 28, 2024 | P00003 | $0 | BAA SETTING PATIENT-CENTRIC QUALITY STANDARDS (PCQS) FOR MODIFIED RELEASE (MR) ORAL DRUG PRODUCTS WITH BIOPREDICTIVE IN VITRO DISSOLUTION-MODELS |
| Sep 20, 2023 | P00002 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE. |
| Mar 24, 2022 | P00001 | $0 | IPP INSTRUCTIONS AND CLAUSES |
| Sep 22, 2020 | 0 | $2.2M | BAA SETTING PATIENT-CENTRIC QUALITY STANDARDS (PCQS) FOR MODIFIED RELEASE (MR) ORAL DRUG PRODUCTS WITH BIOPREDICTIVE IN VITRO DISSOLUTION-MODELS |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.